Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Summary

This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients would normally receive.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Anatomic Stage I Breast Cancer
• Anatomic Stage II Breast Cancer
• Anatomic Stage III Breast Cancer
• Invasive Breast Lobular Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Vanderbilt-Ingram Cancer Center

Last updated on ClinicalTrials.gov

August 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites